Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE

Summary

A combination therapy proposed to be evaluated in this trial, consisting of three already registered compounds with a validated disease mechanism and with known safety profiles, targets key proteins in the dysregulated signal network in stroke, and is expected to synergistically result in post-stroke blood-brain barrier stabilization and neuroprotection. The synergistic mode of action will allow for low doses and is expected to reduce possible side effects while maintaining maximal efficacy

Timeline

Start

2022-09-05

Primary completion

2024-02-29

Completion

2024-04-30

Publications

• Casas AI, Nogales C, Szepanowski RD, Elbatreek MH, Anastasi E, Sadegh S, Skelton J, Frank B, Wipat A, Baumbach J, Kleinschnitz C, Schmidt HHHW. Synergistic Network Pharmacology: Preclinical Validation and Clinical Safety in Acute Ischemic Stroke. J Am Heart Assoc. 2025 May 20;14(10):e039098. doi: 10.1161/JAHA.124.039098. Epub 2025 May 15.

Drugs

Indications